AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01042379
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
RxNorm normalized name: Dostarlimab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle
Trial: NCT01042379
Drug: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
RxNorm normalized name: Dostarlimab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle
Trial: NCT01042379
Drug: Amcenestrant
RxNorm normalized name: Amcenestrant
DrugBank: SAR-439459 (DB17864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks
Trial: NCT00917293
Drug: Pyridoxal 5'-Phosphate
RxNorm normalized name: PYRIDOXAL 5'-PHOSPHATE
DrugBank: Pyridoxal phosphate (DB00114)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
Trial: NCT03320876
Drug: filgotinib
RxNorm normalized name: Filgotinib
DrugBank: Filgotinib (DB14845)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: one filgotinib oral tablet once daily.
Trial: NCT02518464
Drug: Ticagrelor 90 mg twice per day
RxNorm normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
Trial: NCT03865888
Drug: Cyclosporins
RxNorm normalized name: Cyclosporine
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporins eye drops to be administered in dry eyes
Trial: NCT01042379
Drug: Amcenestrant + Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
Trial: NCT01042379
Drug: Amcenestrant + Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks
Trial: NCT01042379
Drug: ARX788 + Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks
Trial: NCT03865888
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus eye drops to be administered in dry eyes
Trial: NCT02864901
Drug: KSL-W
RxNorm normalized name: Ketamine Sublingual Wafer
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plaque reducing gum
Trial: NCT00045981
Drug: ALT-711
RxNorm normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01042379
Drug: VV1 + Cemiplimab
RxNorm normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks
Trial: NCT01042379
Drug: Datopotamab deruxtecan
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Datopotamab deruxtecan (DB16410)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
Trial: NCT01042379
Drug: Datopotamab deruxtecan + Durvalumab
RxNorm normalized name: Datopotamab deruxtecan
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
Trial: NCT01042379
Drug: Zanidatamab
RxNorm normalized name: Zanidatamab
DrugBank: Zanidatamab (DB15471)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks
Trial: NCT01042379
Drug: Lasofoxifene
RxNorm normalized name: lasofoxifene
DrugBank: Lasofoxifene (DB06202)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
Trial: NCT00021372
Drug: estramustine phosphate sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00021372
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01042379
Drug: Z-endoxifen
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-endoxifen: 10 mg QD, p.o., for 24 weeks
Trial: NCT01042379
Drug: ARV-471
RxNorm normalized name: Arv-110 (protac)
DrugBank: Bavdegalutamide (DB19032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARV-471: 200 mg QD, p.o, for 24 weeks
Trial: NCT01042379
Drug: ARV-471 + Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks
Trial: NCT01042379
Drug: ARV-471 + Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks
Trial: NCT01042379
Drug: Endoxifen + Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks
Trial: NCT01042379
Drug: Rilvegostomig + TDXd
RxNorm normalized name: Rilvegostomig
DrugBank: Rilvegostomig (DB18991)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks
Trial: NCT01042379
Drug: Sarilumab + Cemiplimab + Paclitaxel
RxNorm normalized name: cemiplimab
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
Trial: NCT03746249
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (or 8 mg) once daily (QD) oral dosing.
Trial: NCT03746249
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3mg/kg intravenously every 2 weeks
Trial: NCT03313401
Drug: Aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal aflibercept injection
Trial: NCT01258452
Drug: CHF 5074
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is administered to subject in a fasting state
Trial: NCT01258452
Drug: CHF 5974
RxNorm normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug is administered to subject after consumption of a high fat, high calorie meal
Trial: NCT03187899
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
Trial: NCT01314859
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * Oral Treatment with Nifedipine capsules (10mg)~  * Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).~ * Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.~* Maximum Duration of the treatment: 48 hours.
Trial: NCT01314859
Drug: Atosiban
RxNorm normalized name: atosiban
DrugBank: Atosiban (DB09059)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: * Intravenously Treatment with Atosiban (7.5mg/ml)~  * Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.~ * Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.~* Maximum Duration of the treatment: 48 hours.
Trial: NCT00563706
Drug: vabicaserin
RxNorm normalized name: Vabicaserin
DrugBank: Vabicaserin (DB12071)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
Trial: NCT00563706
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT06103656
Drug: Drug: Omalizumab
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 months course, starting 2 months pre-OIT through the 2 month build-up phase
Trial: NCT02622906
Drug: Pasireotide
RxNorm normalized name: Pasireotide
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg per month of the Pasireotide during 6 months
Trial: NCT00633542
Drug: thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/day orally until progression or severe toxicity
Trial: NCT00633542
Drug: interferon alpha
RxNorm normalized name: Interferon alpha-2a
DrugBank: Interferon alfa (DB05258)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 MU 3 times a week until progression or severe toxicity
Trial: NCT02116335
Drug: Bosentan
RxNorm normalized name: Bosentan
DrugBank: Bosentan (DB00559)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
Trial: NCT00729846
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
Trial: NCT00174772
Drug: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
Trial: NCT00174772
Drug: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
Trial: NCT00266565
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10mg/kg (max 750 ml) once a month for 3 months
Trial: NCT04434378
Drug: Tamsulosin
RxNorm normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mg tamsulosin will be given to a randomized group of patients
Trial: NCT01836094
Drug: Methylene Blue (USP grade, 280mg oral)
RxNorm normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00720018
Drug: NP101 Sumatriptan Iontophoretic Transdermal Patch
RxNorm normalized name: Sumatriptan Iontophoretic Transdermal System
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NP101 transdermal patch delivering sumatriptan for 4 hours.
Trial: NCT04008797
Drug: E7386
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: E7386 dosing.
Trial: NCT04008797
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib, capsules, orally.
Trial: NCT04008797
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel dosing.
Trial: NCT04024813
Drug: Seladelpar
RxNorm normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) administered orally once daily
Trial: NCT04024813
Drug: Placebo to match Seladelpar
RxNorm normalized name: Seladelpar
DrugBank: Seladelpar (DB12390)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule(s) administered orally once daily
Trial: NCT00835731
Drug: misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D\&E
Trial: NCT03931135
Drug: IV Cyclizine versus IV Dexamethasone for prevention of nausea and vomiting after intrathecal morphine in patients undergoing cesarean section
RxNorm normalized name: cyclizine / morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first group (Dexamethasone) will receive 8 mg IV dexamethasone within 1-2 minutes after the umbilical cord is clamped.~The second group (Cyclizine) will receive 50 mg cyclizine within 1-2 minutes after the umbilical cord is clamped
Trial: NCT02101164
Drug: pamidronate
RxNorm normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
Trial: NCT04682210
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab 200mg IV Q3W
Trial: NCT04682210
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab 7.5mg/kg IV Q3W
Trial: NCT00896038
Drug: Aprepitant
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
Trial: NCT01160770
Drug: Clobazam
RxNorm normalized name: Clobazam
DrugBank: Clobazam (DB00349)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
Trial: NCT03902249
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00946556
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1g po od for 2 months
Trial: NCT00646607
Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
Trial: NCT00646607
Drug: FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: standard treatment
Trial: NCT04476459
Drug: Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be administered every 3 weeks up to 6 cycles during induction phase, and then every 4 weeks up to 12 cycles in maintenance phase if patients get CR or PR after induction phase.
Trial: NCT04476459
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: dose escalation phase. Patients will oral dosage as 250mg, 500mg or 750mg,qd, per day. Aim to evaluate MTD and DLT, RP2D.~Phase II：Patients continuous oral apatinib as RP2D up to 6 cycles during induction phase, and then 250mg/d up to 1 year in maintenance phase if patients get CR or PR after induction phase.
Trial: NCT00185107
Drug: Colesevelam Hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00185107
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01876628
Drug: Flucloxacillin
RxNorm normalized name: Flucloxacillin
DrugBank: Flucloxacillin (DB00301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous or oral Flucloxacillin. Minimum dose 500mg four times each day. Target duration 5 days less pre-recruitment beta-lactam duration.
Trial: NCT00770575
Drug: Pioglitazone and atorvastatin
RxNorm normalized name: glimepiride and pioglitazone
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:~Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
Trial: NCT00770575
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to~Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks.
Trial: NCT02439359
Drug: CF-301
RxNorm normalized name: Lysin cf-301 (streptococcus suis phage)
DrugBank: Exebacase (DB16161)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation
Trial: NCT01954927
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900 mg.
Trial: NCT03457727
Drug: Danirixin
RxNorm normalized name: Danirixin
DrugBank: Danirixin (DB11922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danirixin is being developed as a potential anti-inflammatory agent for the treatment of chronic obstructive pulmonary disorder (COPD) and other inflammatory diseases and influenza. Danirixin reference (600 mg) or test formulation (475 or 600 mg or 600 mg with 5 percent HPMC) immediate release tablets will be administered by oral route in a cross-over manner.
Trial: NCT03457727
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole is used as an antacid. OMP 40 mg delayed-release capsule will be administered by oral route to randomized subjects.
Trial: NCT00439049
Drug: modafinil
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg daily
Trial: NCT03088280
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: reduced dose (3mg/Kg)
Trial: NCT00439049
Drug: d-amphetamine
RxNorm normalized name: d-amphetamine
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg daily
Trial: NCT00439049
Drug: L-Dopa
RxNorm normalized name: L-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 800/200mg daily
Trial: NCT00439049
Drug: Naltrexone
RxNorm normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg daily
Trial: NCT02600871
Drug: Provodine
RxNorm normalized name: POVIDONE-IODINE 7.5 mg in 1 mL TOPICAL EMULSION [Provodine]
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no